Wilson Sonsini Goodrich & Rosati advised lead investor SR One on the transaction. Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for common dermatologic conditions,...
Veradermics Launches Oversubscribed $150 Million Series C Financing Round
Crystalys Therapeutics Launches With $205 Million Series A Financing to Advance Gout Treatment
Latham & Watkins has advised Crystalys Therapeutics. Wilson Sonsini Goodrich & Rosati has advised Novo Holdings and SR One. Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company,...
Avenzo Therapeutics Raises $60 Million in Series B Financing
Wilson Sonsini Goodrich & Rosati has advised SR One. Avenzo Therapeutics, Inc., a clinical-stage biotechnology company focused on developing next-generation oncology therapies, has closed a $60...
Odyssey Therapeutics Closes $213 Million Series D Financing
Wilson Sonsini Goodrich & Rosati has advised SR One as lead investor. Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the closing of a $213...
Avalyn Pharma Closes $100 Million Oversubscribed Series D Financing
Goodwin Procter advised Avalyn Pharma Inc., and Wilson Sonsini Goodrich & Rosati has advised SR One and Novo Holdings on the transaction. Avalyn Pharma Inc., a...
Zenas BioPharma’s Upsized $200 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
SR One’s $600 Million Second Venture Fund Formation
Kirkland & Ellis advised SR One on the deal. SR One announced the close of its second fund at over $600 million, substantially exceeding its target of...
Rezo Therapeutics’ $78 Million Series A Financing
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
ADARx’s $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
ARS Pharmaceuticals’ $55 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...